Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage company focused on creating small molecule drugs for inflammatory and fibrotic conditions, particularly kidney diseases, announced today that its management team will be presenting at the following investor conferences:
mwb online Health Care Conference
Date: July 1, 2025
Presentation Time: 12:00 pm CEST
Attendees: Frank Weber, CEO; Julia Neugebauer, COO
Virtual conference
Link to conference
H.C. Wainwright 4th Annual Kidney Virtual Conference
Date: July 14, 2025
Presentation Time: 3:00 pm CEST / 9:00 am EDT
Attendees: Frank Weber, CEO; Julia Neugebauer, COO
Virtual conference
Link to conference
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotech company developing innovative, small molecule-based treatments for inflammatory and fibrotic kidney disorders. Driven by its passion for innovative science, the Company aims to improve patient outcomes by altering the progression of serious diseases through the modulation of the activity and stability of disease-relevant proteins. Vivoryon’s lead program, varoglutamstat, a unique, orally available QPCT/L inhibitor, is currently being assessed as a potential treatment for diabetic kidney disease.
Vivoryon Forward Looking Statements
This press release contains forward-looking statements regarding the business strategy, management plans, and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), as well as estimates, projections, forecasts, and statements concerning the market for the Company’s products and their potential availability. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” and similar expressions, are intended to identify these forward-looking statements. These statements are not guarantees of future performance but are based on current expectations and assumptions about future events, trends, the economy, and other conditions. Forward-looking statements involve known and unknown risks and uncertainties that could significantly affect the outcome and financial impact of the plans and events described. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies, or events may differ materially from those expressed or implied in such statements and from expectations. Therefore, undue reliance should not be placed on these statements. This press release does not list risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the Company’s published annual financial statements. This press release, including any forward-looking statements, is relevant only as of the date of its release. The Company assumes no obligation to update any information or forward-looking statements contained herein, except as required by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email:
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email:
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email:
Attachment
“`